Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.
AuthorStephens, Deborah M
LeBlanc, Michael L
Puvvada, Soham D
Friedberg, Jonathan W
Smith, Sonali M
MetadataShow full item record
PublisherAMER SOC CLINICAL ONCOLOGY
CitationContinued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. 2016, 34 (25):2997-3004 J. Clin. Oncol.
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
RightsCopyright © 2016, American Society of Clinical Oncology.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractUtility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) and overall survival (OS) compared with eight cycles of CHOP (CHOP8). Subsequent analysis showed an unexpected overlap of the PFS curves. We aimed to confirm and investigate this observation by performing long-term analysis of SWOG S8736 and evaluating these data alongside data from similar patients receiving rituximab and CHOP3RT (SWOG S0014 study).
NotePublished online ahead of print at www.jco.org on July 5, 2016. 12 month embargo.
VersionFinal published version
SponsorsNational Institutes of Health (NIH)/National Cancer Institute (NCI)/National Clinical Trials Network [CA180888, CA180819, CA180801, CA 180834, CA 180846, CA180835, CA180818, CA180830, CA180828]; NIH/NCI Community Oncology Research Program Grants [CA189953, CA189952, CA189954, CA189808, CA189830, CA189957, CA189822, CA189853, CA189860]
- Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
- Authors: Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP, Southwest Oncology Group.
- Issue date: 2008 May 10
- Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
- Authors: Kwon J, Kim IH, Kim BH, Kim TM, Heo DS
- Issue date: 2015 May 1
- Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
- Authors: Kumar A, Lunning MA, Zhang Z, Migliacci JC, Moskowitz CH, Zelenetz AD
- Issue date: 2015 Dec
- Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
- Authors: Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS
- Issue date: 2010 Sep 20
- Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
- Authors: Shi Z, Das S, Okwan-Duodu D, Esiashvili N, Flowers C, Chen Z, Wang X, Jiang K, Nastoupil LJ, Khan MK
- Issue date: 2013 Jul 1